{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T14:10:46Z","timestamp":1789049446866,"version":"build-2803163510"},"reference-count":102,"publisher":"Pharmaceutical Society of Japan","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biological &amp; Pharmaceutical Bulletin","Biol. Pharm. Bull."],"published-print":{"date-parts":[[2025,9,1]]},"DOI":"10.1248\/bpb.b25-00235","type":"journal-article","created":{"date-parts":[[2025,8,31]],"date-time":"2025-08-31T22:09:33Z","timestamp":1756678173000},"page":"1287-1294","source":"Crossref","is-referenced-by-count":3,"title":["Trastuzumab Cardiotoxicity: Mechanism and Management"],"prefix":"10.1248","volume":"48","author":[{"given":"Minoru","family":"Wakasa","sequence":"first","affiliation":[{"name":"Department of Cardiology, Kanazawa Medical University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miharu","family":"Masaki","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Kanazawa Medical University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kouji","family":"Kajinami","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Kanazawa Medical University"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"163","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1) Hudis CA. Trastuzumab\u2014mechanism of action and use in clinical practice. <i>N. Engl. J. Med.<\/i>, <b>357<\/b>, 39\u201351 (2007).","DOI":"10.1056\/NEJMra043186"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2) Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J, Norton L. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. <i>N. Engl. J. Med.<\/i>, <b>344<\/b>, 783\u2013792 (2001).","DOI":"10.1056\/NEJM200103153441101"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3) Ross JS, Fletcher JA. The HER-2\/neu oncogene in breast cancer: prognostic factor, predictive factor, and target for therapy, <i>Stem Cells<\/i>, <b>16<\/b>, 413\u2013428 (1998).","DOI":"10.1002\/stem.160413"},{"key":"4","unstructured":"4) Valicsek E, K\u00f3sz\u00f3 R, Dobi \u00c1, Uhercs\u00e1k G, Varga Z, Vass A, Jebelovszky \u00c9, Kah\u00e1n Z. Cardiac surveillance findings during adjuvant and palliative trastuzumab therapy in patients with breast cancer. <i>Anticancer Res.<\/i>, <b>35<\/b>, 4967\u20134973 (2015)."},{"key":"5","doi-asserted-by":"crossref","unstructured":"5) Ban M, Petri\u0107 Mi\u0161e B, Vrdoljak E. Early HER2-positive breast cancer: current treatment and novel approaches. <i>Breast Care<\/i> (Basel), <b>15<\/b>, 560\u2013569 (2020).","DOI":"10.1159\/000511883"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6) Tesch ME, Gelmon KA. Targeting HER2 in breast cancer: latest developments on treatment sequencing and the introduction of biosimilars. <i>Drugs<\/i>, <b>80<\/b>, 1811\u20131830 (2020).","DOI":"10.1007\/s40265-020-01411-y"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7) Seidman A, Hudis C, Pierri MK, Shak S, Paton V, Ashby M, Murphy M, Stewart SJ, Keefe D. Cardiac dysfunction in the trastuzumab clinical trials experience. <i>J. Clin. Oncol.<\/i>, <b>20<\/b>, 1215\u20131221 (2002).","DOI":"10.1200\/JCO.2002.20.5.1215"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8) Perez EA, Rodeheffer R. Clinical cardiac tolerability of trastuzumab. <i>J. Clin. Oncol.<\/i>, <b>22<\/b>, 322\u2013329 (2004).","DOI":"10.1200\/JCO.2004.01.120"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9) Florido R, Smith KL, Cuomo KK, Russell SD. Cardiotoxicity from human epidermal growth factor receptor-2 (HER2) targeted therapies. <i>J. Am. Heart Assoc.<\/i>, <b>6<\/b>, e006915 (2017).","DOI":"10.1161\/JAHA.117.006915"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10) Seidman AD, Fornier MN, Esteva FJ, <i>et al.<\/i> Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by <i>HER2<\/i> immunophenotype and gene amplification. <i>J. Clin. Oncol.<\/i>, <b>19<\/b>, 2587\u20132595 (2001).","DOI":"10.1200\/JCO.2001.19.10.2587"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11) Guarneri V, Lenihan DJ, Valero V, Durand JB, Broglio K, Hess KR, Michaud LB, Gonzalez-Angulo AM, Hortobagyi GN, Esteva FJ. Long-term cardiac tolerability of trastuzumab in metastatic breast cancer: the M.D. Anderson Cancer Center experience. <i>J. Clin. Oncol.<\/i>, <b>24<\/b>, 4107\u20134115 (2006).","DOI":"10.1200\/JCO.2005.04.9551"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12) Suter TM, Procter M, van Veldhuisen DJ, Muscholl M, Bergh J, Carlomagno C, Perren T, Passalacqua R, Bighin C, Klijn JG, Ageev FT, Hitre E, Groetz J, Iwata H, Knap M, Gnant M, Muehlbauer S, Spence A, Gelber RD, Piccart-Gebhart MJ. Trastuzumab-associated cardiac adverse effects in the Herceptin adjuvant trial. <i>J. Clin. Oncol.<\/i>, <b>25<\/b>, 3859\u20133865 (2007).","DOI":"10.1200\/JCO.2006.09.1611"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13) Crone SA, Zhao YY, Fan L, Gu Y, Minamisawa S, Liu Y, Peterson KL, Chen J, Kahn R, Condorelli G, Ross J Jr, Chien KR, Lee K-F. ErbB2 is essential in the prevention of dilated cardiomyopathy. <i>Nat. Med.<\/i>, <b>8<\/b>, 459\u2013465 (2002).","DOI":"10.1038\/nm0502-459"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14) Ewer MS, Vooletich MT, Durand JB, Woods ML, Davis JR, Valero V, Lenihan DJ. Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment. <i>J. Clin. Oncol.<\/i>, <b>23<\/b>, 7820\u20137826 (2005).","DOI":"10.1200\/JCO.2005.13.300"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15) Negro A, Brar BK, Lee KF. Essential roles of Her2\/erbB2 in cardiac development and function. <i>Recent Prog. Horm. Res.<\/i>, <b>59<\/b>, 1\u201312 (2004).","DOI":"10.1210\/rp.59.1.1"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16) Garratt AN, Ozcelik C, Birchmeier C. ErbB2 pathways in heart and neural diseases. <i>Trends Cardiovasc. Med.<\/i>, <b>13<\/b>, 80\u201386 (2003).","DOI":"10.1016\/S1050-1738(02)00231-1"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17) Dogan I, Cumaoglu A, Aricioglu A, Ekmekci A. Inhibition of ErbB2 by Herceptin reduces viability and survival, induces apoptosis and oxidative stress in Calu-3 cell line. <i>Mol. Cell. Biochem.<\/i>, <b>347<\/b>, 41\u201351 (2011).","DOI":"10.1007\/s11010-010-0610-7"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18) Yu AF, Yadav NU, Lung BY, Eaton AA, Thaler HT, Hudis CA, Dang CT, Steingart RM. Trastuzumab interruption and treatment-induced cardiotoxicity in early HER2-positive breast cancer. <i>Breast Cancer Res. Treat.<\/i>, <b>149<\/b>, 489\u2013495 (2015).","DOI":"10.1007\/s10549-014-3253-7"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19) Cardinale D, Sandri MT, Colombo A, Colombo N, Boeri M, Lamantia G, Civelli M, Peccatori F, Martinelli G, Fiorentini C, Cipolla CM. Prognostic value of troponin i in cardiac risk stratification of cancer patients undergoing high-dose chemotherapy. <i>Circulation<\/i>, <b>109<\/b>, 2749\u20132754 (2004).","DOI":"10.1161\/01.CIR.0000130926.51766.CC"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20) Prat A, Pineda E, Adamo B, Galv\u00e1n P, Fern\u00e1ndez A, Gaba L, D\u00edez M, Viladot M, Arance A, Mu\u00f1oz M. Clinical implications of the intrinsic molecular subtypes of breast cancer. <i>Breast<\/i>, <b>24<\/b> (Suppl. 2), S26\u2013S35 (2015).","DOI":"10.1016\/j.breast.2015.07.008"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21) Fan C, Oh DS, Wessels L, Weigelt B, Nuyten DSA, Nobel AB, van\u2019t Veer LJ, Perou CM. Concordance among gene-expression\u2013based predictors for breast cancer. <i>N. Engl. J. Med.<\/i>, <b>355<\/b>, 560\u2013569 (2006).","DOI":"10.1056\/NEJMoa052933"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22) Parise C, Caggiano V. Disparities in the risk of the ER\/PR\/HER2 breast cancer subtypes among Asian Americans in California. <i>Cancer Epidemiol.<\/i>, <b>38<\/b>, 556\u2013562 (2014).","DOI":"10.1016\/j.canep.2014.08.001"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23) Millikan RC, Newman B, Tse CK, Moorman PG, Conway K, Dressler LG, Smith LV, Labbok MH, Geradts J, Bensen JT, Jackson S, Nyante S, Livasy C, Carey L, Earp HS, Perou CM. Epidemiology of basal-like breast cancer. <i>Breast Cancer Res. Treat.<\/i>, <b>109<\/b>, 123\u2013139 (2008).","DOI":"10.1007\/s10549-007-9632-6"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24) Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2\/neu oncogene. <i>Science<\/i>, <b>235<\/b>, 177\u2013182 (1987).","DOI":"10.1126\/science.3798106"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25) Amodio R, Zarcone M, Cusimano R, Campisi I, Dolcemascolo C, Traina A, Agostara B, Romano N. Target therapy in HER2-overexpressing breast cancer patients. <i>OMICS<\/i>, <b>15<\/b>, 363\u2013367 (2011).","DOI":"10.1089\/omi.2010.0125"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26) Cobleigh MA, Vogel CL, Tripathy D, Robert NJ, Scholl S, Fehrenbacher L, Wolter JM, Paton V, Shak S, Lieberman G, Slamon DJ. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. <i>J. Clin. Oncol.<\/i>, <b>17<\/b>, 2639\u20132648 (1999).","DOI":"10.1200\/JCO.1999.17.9.2639"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27) Nemeth BT, Varga ZV, Wu WJ, Pacher P. Trastuzumab cardiotoxicity: from clinical trials to experimental studies. <i>Br. J. Pharmacol.<\/i>, <b>174<\/b>, 3727\u20133748 (2017).","DOI":"10.1111\/bph.13643"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28) Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. <i>Nat. Rev. Mol. Cell Biol.<\/i>, <b>2<\/b>, 127\u2013137 (2001).","DOI":"10.1038\/35052073"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29) Karunagaran D, Tzahar E, Beerli RR, Chen X, Graus-Porta D, Ratzkin BJ, Seger R, Hynes NE, Yarden Y. ErbB-2 is a common auxiliary subunit of NDF and EGF receptors: implications for breast cancer. <i>EMBO J.<\/i>, <b>15<\/b>, 254\u2013264 (1996).","DOI":"10.1002\/j.1460-2075.1996.tb00356.x"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30) Kraus MH, Popescu NC, Amsbaugh SC, King CR. Overexpression of the EGF receptor-related proto-oncogene erbB-2 in human mammary tumor cell lines by different molecular mechanisms. <i>EMBO J.<\/i>, <b>6<\/b>, 605\u2013610 (1987).","DOI":"10.1002\/j.1460-2075.1987.tb04797.x"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31) Galindo CL, Ryzhov S, Sawyer DB. Neuregulin as a heart failure therapy and mediator of reverse remodeling. <i>Curr. Heart Fail. Rep.<\/i>, <b>11<\/b>, 40\u201349 (2014).","DOI":"10.1007\/s11897-013-0176-2"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32) Varga ZV, Ferdinandy P, Liaudet L, Pacher P. Drug-induced mitochondrial dysfunction and cardiotoxicity. <i>Am. J. Physiol. Heart Circ. Physiol.<\/i>, <b>309<\/b>, H1453\u2013H1467 (2015).","DOI":"10.1152\/ajpheart.00554.2015"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33) Odiete O, Hill MF, Sawyer DB. Neuregulin in cardiovascular development and disease. <i>Circ. Res.<\/i>, <b>111<\/b>, 1376\u20131385 (2012).","DOI":"10.1161\/CIRCRESAHA.112.267286"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34) Pentassuglia L, Timolati F, Seifriz F, Abudukadier K, Suter TM, Zuppinger C. Inhibition of ErbB2\/neuregulin signaling augments paclitaxel-induced cardiotoxicity in adult ventricular myocytes. <i>Exp. Cell Res.<\/i>, <b>313<\/b>, 1588\u20131601 (2007).","DOI":"10.1016\/j.yexcr.2007.02.007"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35) Fedele C, Riccio G, Malara AE, D\u2019Alessio G, De Lorenzo C. Mechanisms of cardiotoxicity associated with ErbB2 inhibitors. <i>Breast Cancer Res. Treat.<\/i>, <b>134<\/b>, 595\u2013602 (2012).","DOI":"10.1007\/s10549-012-2103-8"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36) Abete P, Napoli C, Santoro G, Ferrara N, Tritto I, Chiariello M, Rengo F, Ambrosio G. Age-related decrease in cardiac tolerance to oxidative stress. <i>J. Mol. Cell. Cardiol.<\/i>, <b>31<\/b>, 227\u2013236 (1999).","DOI":"10.1006\/jmcc.1998.0862"},{"key":"37","doi-asserted-by":"crossref","unstructured":"37) Rohrbach S, Muller-Werdan U, Werdan K, Koch S, Gellerich NF, Holtz J. Apoptosis-modulating interaction of the neuregulin\/erbB pathway with antracyclines in regulating Bcl-xS and Bcl-xL in cardiomyocytes. <i>J. Mol. Cell. Cardiol.<\/i>, <b>38<\/b>, 485\u2013493 (2005).","DOI":"10.1016\/j.yjmcc.2004.12.013"},{"key":"38","doi-asserted-by":"crossref","unstructured":"38) Gorini S, De Angelis A, Berrino L, Malara N, Rosano G, Ferraro E. Corrigendum to \u201cChemotherapeutic Drugs and Mitochondrial Dysfunction: Focus on Doxorubicin, Trastuzumab, and Sunitinib\u201d. <i>Oxid. Med. Cell. Longev.<\/i>, <b>2019<\/b>, 9601435 (2019).","DOI":"10.1155\/2019\/9601435"},{"key":"39","doi-asserted-by":"crossref","unstructured":"39) Siddiqa A, Long LM, Li L, Marciniak RA, Kazhdan I. Expression of HER-2 in MCF-7 breast cancer cells modulates anti-apoptotic proteins Survivin and Bcl-2 <i>via<\/i> the extracellular signal-related kinase (ERK) and phosphoinositide-3 kinase (PI3K) signalling pathways. <i>BMC Cancer<\/i>, <b>8<\/b>, 129 (2008).","DOI":"10.1186\/1471-2407-8-129"},{"key":"40","doi-asserted-by":"crossref","unstructured":"40) Wang Y, Wei J, Zhang P, Zhang X, Wang Y, Chen W, Zhao Y, Cui X. Neuregulin-1, a potential therapeutic target for cardiac repair. <i>Front. Pharmacol.<\/i>, <b>13<\/b>, 945206 (2022).","DOI":"10.3389\/fphar.2022.945206"},{"key":"41","doi-asserted-by":"crossref","unstructured":"41) Mohan N, Shen Y, Endo Y, ElZarrad MK, Wu WJ. Trastuzumab, but not pertuzumab, dysregulates HER2 signaling to mediate inhibition of autophagy and increase in reactive oxygen species production in human cardiomyocytes. <i>Mol. Cancer Ther.<\/i>, <b>15<\/b>, 1321\u20131331 (2016).","DOI":"10.1158\/1535-7163.MCT-15-0741"},{"key":"42","unstructured":"42) Mohan N, Jiang J, Wu WJ. Implications of autophagy and oxidative stress in trastuzumab-mediated cardiac toxicities. <i>Austin Pharmacol. Pharm.<\/i>, <b>2<\/b>, 1005 (2017)."},{"key":"43","doi-asserted-by":"crossref","unstructured":"43) Janser FA, Tschan MP, Langer R. The role of autophagy in HER2-targeted therapy. <i>Swiss Med. Wkly.<\/i>, <b>149<\/b>, w20138 (2019).","DOI":"10.4414\/smw.2019.20138"},{"key":"44","doi-asserted-by":"crossref","unstructured":"44) Jie B, Zhang X, Wu X, Xin Y, Liu Y, Guo Y. Neuregulin-1 suppresses cardiomyocyte apoptosis by activating PI3K\/Akt and inhibiting mitochondrial permeability transition pore. <i>Mol. Cell. Biochem.<\/i>, <b>370<\/b>, 35\u201343 (2012).","DOI":"10.1007\/s11010-012-1395-7"},{"key":"45","doi-asserted-by":"crossref","unstructured":"45) Vermeulen Z, Segers VFM, De Keulenaer GW. ErbB2 signaling at the crossing between heart failure and cancer. <i>Basic Res. Cardiol.<\/i>, <b>111<\/b>, 60 (2016).","DOI":"10.1007\/s00395-016-0576-z"},{"key":"46","doi-asserted-by":"crossref","unstructured":"46) Copeland-Halperin RS, Liu JE, Yu AF. Cardiotoxicity of HER2-targeted therapies. <i>Curr. Opin. Cardiol.<\/i>, <b>34<\/b>, 451\u2013458 (2019).","DOI":"10.1097\/HCO.0000000000000637"},{"key":"47","doi-asserted-by":"crossref","unstructured":"47) Gianni L, Eiermann W, Semiglazov V, Manikhas A, Lluch A, Tjulandin S, Zambetti M, Vazquez F, Byakhow M, Lichinitser M, Climent MA, Ciruelos E, Ojeda B, Mansutti M, Bozhok A, Baronio R, Feyereislova A, Barton C, Valagussa P, Baselga J. Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab <i>versus<\/i> neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort. <i>Lancet<\/i>, <b>375<\/b>, 377\u2013384 (2010).","DOI":"10.1016\/S0140-6736(09)61964-4"},{"key":"48","unstructured":"48) Zeglinski M, Ludke A, Jassal DS, Singal PK. Trastuzumab-induced cardiac dysfunction: a \u2018dual-hit\u2019. <i>Exp. Clin. Cardiol.<\/i>, <b>16<\/b>, 70\u201374 (2011)."},{"key":"49","doi-asserted-by":"crossref","unstructured":"49) Wu Q, Bai B, Tian C, Li D, Yu H, Song B, Li B, Chu X. The molecular mechanisms of cardiotoxicity induced by HER2, VEGF, and tyrosine kinase inhibitors: an updated review. <i>Cardiovasc. Drugs Ther.<\/i>, <b>36<\/b>, 511\u2013524 (2022).","DOI":"10.1007\/s10557-021-07181-3"},{"key":"50","doi-asserted-by":"crossref","unstructured":"50) Lankhorst S, Danser AHJ, van den Meiracker AH. Endothelin-1 and antiangiogenesis. <i>Am. J. Physiol. Regul. Integr. Comp. Physiol.<\/i>, <b>310<\/b>, R230\u2013R234 (2016).","DOI":"10.1152\/ajpregu.00373.2015"},{"key":"51","doi-asserted-by":"crossref","unstructured":"51) Zardavas D, Suter TM, Van Veldhuisen DJ, Steinseifer J, Noe J, Lauer S, Al-Sakaff N, Piccart-Gebhart MJ, de Azambuja E. Role of troponins I and T and <i>N<\/i>-terminal prohormone of brain natriuretic peptide in monitoring cardiac safety of patients with early-stage human epidermal growth factor receptor 2\u2013positive breast cancer receiving trastuzumab: a Herceptin adjuvant study cardiac marker substudy. <i>J. Clin. Oncol.<\/i>, <b>35<\/b>, 878\u2013884 (2017).","DOI":"10.1200\/JCO.2015.65.7916"},{"key":"52","unstructured":"52) Lyon AR, L\u00f3pez-Fern\u00e1ndez T, Couch LS, <i>et al.<\/i> 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). <i>Eur. Heart J.<\/i>, <b>43<\/b>, 4229\u20134361 (2022)."},{"key":"53","doi-asserted-by":"crossref","unstructured":"53) Slamon D, Eiermann W, Robert N, <i>et al.<\/i> Adjuvant trastuzumab in HER2-positive breast cancer. <i>N. Engl. J. Med.<\/i>, <b>365<\/b>, 1273\u20131283 (2011).","DOI":"10.1056\/NEJMoa0910383"},{"key":"54","doi-asserted-by":"crossref","unstructured":"54) Pond\u00e9 N, Ameye L, Lambertini M, Paesmans M, Piccart M, de Azambuja E. Trastuzumab emtansine (T-DM1)-associated cardiotoxicity: pooled analysis in advanced HER2-positive breast cancer. <i>Eur. J. Cancer<\/i>, <b>126<\/b>, 65\u201373 (2020).","DOI":"10.1016\/j.ejca.2019.11.023"},{"key":"55","doi-asserted-by":"crossref","unstructured":"55) Zamorano JL, Lancellotti P, Rodriguez Mu\u00f1oz D, Aboyans V, Asteggiano R, Galderisi M, Habib G, Lenihan DJ, Lip GYH, Lyon AR, Lopez Fernandez T, Mohty D, Piepoli MF, Tamargo J, Torbicki A, Suter TM. 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: the Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). <i>Eur. Heart J.<\/i>, <b>37<\/b>, 2768\u20132801 (2016).","DOI":"10.1093\/eurheartj\/ehw211"},{"key":"56","doi-asserted-by":"crossref","unstructured":"56) Plana JC, Galderisi M, Barac A, <i>et al.<\/i> Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. <i>J. Am. Soc. Echocardiogr.<\/i>, <b>27<\/b>, 911\u2013939 (2014).","DOI":"10.1016\/j.echo.2014.07.012"},{"key":"57","doi-asserted-by":"crossref","unstructured":"57) Houbois CP, Nolan M, Somerset E, Shalmon T, Esmaeilzadeh M, Lamacie MM, Amir E, Brezden-Masley C, Koch CA, Thevakumaran Y, Yan AT, Marwick TH, Wintersperger BJ, Thavendiranathan P. Serial cardiovascular magnetic resonance strain measurements to identify cardiotoxicity in breast cancer. <i>JACC Cardiovasc. Imaging<\/i>, <b>14<\/b>, 962\u2013974 (2021).","DOI":"10.1016\/j.jcmg.2020.09.039"},{"key":"58","doi-asserted-by":"crossref","unstructured":"58) Ferreira VM, Schulz-Menger J, Holmvang G, Kramer CM, Carbone I, Sechtem U, Kindermann I, Gutberlet M, Cooper LT, Liu P, Friedrich MG. Cardiovascular magnetic resonance in nonischemic myocardial inflammation. <i>J. Am. Coll. Cardiol.<\/i>, <b>72<\/b>, 3158\u20133176 (2018).","DOI":"10.1016\/j.jacc.2018.09.072"},{"key":"59","doi-asserted-by":"crossref","unstructured":"59) Skouri HN, Dec GW, Friedrich MG, Cooper LT. Noninvasive Imaging in Myocarditis. <i>J. Am. Coll. Cardiol.<\/i>, <b>48<\/b>, 2085\u20132093 (2006).","DOI":"10.1016\/j.jacc.2006.08.017"},{"key":"60","doi-asserted-by":"crossref","unstructured":"60) Fallah-Rad N, Lytwyn M, Fang T, Kirkpatrick I, Jassal DS. Delayed contrast enhancement cardiac magnetic resonance imaging in trastuzumab induced cardiomyopathy. <i>J. Cardiovasc. Magn. Reson.<\/i>, <b>10<\/b>, 5 (2008).","DOI":"10.1186\/1532-429X-10-5"},{"key":"61","doi-asserted-by":"crossref","unstructured":"61) Gal\u00e1n-Arriola C, Lobo M, V\u00edlchez-Tschischke JP, L\u00f3pez GJ, de Molina-Iracheta A, P\u00e9rez-Mart\u00ednez C, Ag\u00fcero J, Fern\u00e1ndez-Jim\u00e9nez R, Mart\u00edn-Garc\u00eda A, Oliver E, Villena-Gutierrez R, Pizarro G, S\u00e1nchez PL, Fuster V, S\u00e1nchez-Gonz\u00e1lez J, Ibanez B. Serial magnetic resonance imaging to identify early stages of anthracycline-induced cardiotoxicity. <i>J. Am. Coll. Cardiol.<\/i>, <b>73<\/b>, 779\u2013791 (2019).","DOI":"10.1016\/j.jacc.2018.11.046"},{"key":"62","doi-asserted-by":"crossref","unstructured":"62) Hong YJ, Park HS, Park JK, Han K, Park CH, Kim TK, Yoo SJ, Lee JY, Kim PK, Hur J, Lee H-J, Kim YJ, Suh YJ, Paek MY, Choi BW. Early detection and serial monitoring of anthracycline-induced cardiotoxicity using t1-mapping cardiac magnetic resonance imaging: an animal study. <i>Sci. Rep.<\/i>, <b>7<\/b>, 2663 (2017).","DOI":"10.1038\/s41598-017-02627-x"},{"key":"63","doi-asserted-by":"crossref","unstructured":"63) Martin-Garcia A, Diaz-Pelaez E, Lopez-Corral L, Sanchez-Pablo C, Macias de Plasencia G, Galan-Arriola C, Sanchez-Gonzalez J, Cruz JJ, Ibanez B, Sanchez PL. T2 mapping identifies early anthracycline-induced cardiotoxicity in elderly patients with cancer. <i>JACC Cardiovasc. Imaging<\/i>, <b>13<\/b>, 1630\u20131632 (2020).","DOI":"10.1016\/j.jcmg.2020.01.017"},{"key":"64","doi-asserted-by":"crossref","unstructured":"64) Giusca S, Korosoglou G, Montenbruck M, Ger\u0161ak B, Schwarz AK, Esch S, Kelle S, W\u00fclfing P, Dent S, Lenihan D, Steen H. Multiparametric early detection and prediction of cardiotoxicity using myocardial strain, t1 and t2 mapping, and biochemical markers: a longitudinal cardiac resonance imaging study during 2 years of follow-up. <i>Circ. Cardiovasc. Imaging<\/i>, <b>14<\/b>, e012459 (2021).","DOI":"10.1161\/CIRCIMAGING.121.012459"},{"key":"65","doi-asserted-by":"crossref","unstructured":"65) Haaf P, Garg P, Messroghli DR, Broadbent DA, Greenwood JP, Plein S. Cardiac T1 Mapping and Extracellular Volume (ECV) in clinical practice: a comprehensive review. <i>J. Cardiovasc. Magn. Reson.<\/i>, <b>18<\/b>, 89 (2016).","DOI":"10.1186\/s12968-016-0308-4"},{"key":"66","doi-asserted-by":"crossref","unstructured":"66) Mohamed AA, Elmancy LY, Abulola SM, Al-Qattan SA, Mohamed Ibrahim MI, Maayah ZH. Assessment of native myocardial T1 mapping for early detection of anthracycline-induced cardiotoxicity in patients with cancer: a systematic review and meta-analysis. <i>Cardiovasc. Toxicol.<\/i>, <b>24<\/b>, 563\u2013575 (2024).","DOI":"10.1007\/s12012-024-09866-1"},{"key":"67","doi-asserted-by":"crossref","unstructured":"67) Muehlberg F, Funk S, Zange L, von Knobelsdorff-Brenkenhoff F, Blaszczyk E, Schulz A, Ghani S, Reichardt A, Reichardt P, Schulz-Menger J. Native myocardial T1 time can predict development of subsequent anthracycline-induced cardiomyopathy. <i>ESC Heart Fail.<\/i>, <b>5<\/b>, 620\u2013629 (2018).","DOI":"10.1002\/ehf2.12277"},{"key":"68","doi-asserted-by":"crossref","unstructured":"68) Tahir E, Azar M, Shihada S, Seiffert K, Goy Y, Beitzen-Heineke A, Molwitz I, Muellerleile K, Stehning C, Sch\u00f6n G, Adam G, Petersen C, M\u00fcller V, Lund GK. Myocardial injury detected by T1 and T2 mapping on CMR predicts subsequent cancer therapy\u2013related cardiac dysfunction in patients with breast cancer treated by epirubicin-based chemotherapy or left-sided RT. <i>Eur. Radiol.<\/i>, <b>32<\/b>, 1853\u20131865 (2022).","DOI":"10.1007\/s00330-021-08260-7"},{"key":"69","doi-asserted-by":"crossref","unstructured":"69) Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J, Norton L. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. <i>N. Engl. J. Med.<\/i>, <b>344<\/b>, 783\u2013792 (2001).","DOI":"10.1056\/NEJM200103153441101"},{"key":"70","doi-asserted-by":"crossref","unstructured":"70) Ganz PA, Romond EH, Cecchini RS, Rastogi P, Geyer CE Jr, Swain SM, Jeong J-H, Fehrenbacher L, Gross HM, Brufsky AM, Flynn PJ, Wahl TA, Seay TE, Wade JL 3rd, Biggs DD, Atkins JN, Polikoff J, Zapas JL, Mamounas EP, Wolmark N. Long-term follow-up of cardiac function and quality of life for patients in NSABP protocol B-31\/NRG oncology: a randomized trial comparing the safety and efficacy of doxorubicin and cyclophosphamide (AC) followed by paclitaxel with ac followed by paclitaxel and trastuzumab in patients with node-positive breast cancer with tumors overexpressing human epidermal growth factor receptor 2. <i>J. Clin. Oncol.<\/i>, <b>35<\/b>, 3942\u20133948 (2017).","DOI":"10.1200\/JCO.2017.74.1165"},{"key":"71","doi-asserted-by":"crossref","unstructured":"71) Curigliano G, Lenihan D, Fradley M, <i>et al.<\/i> Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations. <i>Ann. Oncol.<\/i>, <b>31<\/b>, 171\u2013190 (2020).","DOI":"10.1016\/j.annonc.2019.10.023"},{"key":"72","doi-asserted-by":"crossref","unstructured":"72) Pareek N, Cevallos J, Moliner P, Shah M, Tan LL, Chambers V, Baski AJ, Khattar RS, Shaema R, Rosen S, Lyon A. Activity and outcomes of a cardio-oncology service in the United Kingdom\u2014a five-year experience. <i>Eur. J. Heart Fail.<\/i>, <b>20<\/b>, 1721\u20131731 (2018).","DOI":"10.1002\/ejhf.1292"},{"key":"73","doi-asserted-by":"crossref","unstructured":"73) Lynce F, Barac A, Geng X, Dang C, Yu AF, Smith KL, Gallagher C, Pohlmann PR, Nunes R, Herbolsheimer P, Warren R, Srichai MB, Hofmeyer M, Cunningham A, Timothee P, Asch FM, Shajahan-Haq A, Tan MT, Isaacs C, Swain SM. Prospective evaluation of the cardiac safety of HER2-targeted therapies in patients with HER2-positive breast cancer and compromised heart function: the SAFE-HEaRt study. <i>Breast Cancer Res. Treat.<\/i>, <b>175<\/b>, 595\u2013603 (2019).","DOI":"10.1007\/s10549-019-05191-2"},{"key":"74","doi-asserted-by":"crossref","unstructured":"74) Lenihan DJ, Stevens PL, Massey M, Plana JC, Araujo DM, Fanale MA, Fayad LE, Fisch MJ, Yeh ETH. The utility of point-of-care biomarkers to detect cardiotoxicity during anthracycline chemotherapy: a feasibility study. <i>J. Card. Fail.<\/i>, <b>22<\/b>, 433\u2013438 (2016).","DOI":"10.1016\/j.cardfail.2016.04.003"},{"key":"75","doi-asserted-by":"crossref","unstructured":"75) Leong DP, Cosman T, Alhussein MM, Kumar Tyagi N, Karampatos S, Barron CC, Wright D, Tandon V, Magloire P, Joseph P, Conen D, Devereaux PJ, Ellis PM, Mukherjee SD, Dhesy-Thind S. Safety of continuing trastuzumab despite mild cardiotoxicity. <i>JACC CardioOncol.<\/i>, <b>1<\/b>, 1\u201310 (2019).","DOI":"10.1016\/j.jaccao.2019.06.004"},{"key":"76","doi-asserted-by":"crossref","unstructured":"76) Omland T, Heck SL, Gulati G. The Role of Cardioprotection in Cancer Therapy Cardiotoxicity: JACC: CardioOncology state-of-the-art review. <i>JACC CardioOncol.<\/i>, <b>4<\/b>, 19\u201337 (2022).","DOI":"10.1016\/j.jaccao.2022.01.101"},{"key":"77","doi-asserted-by":"crossref","unstructured":"77) Guglin M, Krischer J, Tamura R, Fink A, Bello-Matricaria L, McCaskill-Stevens W, Munster PN. Randomized trial of lisinopril versus carvedilol to prevent trastuzumab cardiotoxicity in patients with breast cancer. <i>J. Am. Coll. Cardiol.<\/i>, <b>73<\/b>, 2859\u20132868 (2019).","DOI":"10.1016\/j.jacc.2019.03.495"},{"key":"78","doi-asserted-by":"crossref","unstructured":"78) Seicean S, Seicean A, Alan N, Plana JC, Budd GT, Marwick TH. Cardioprotective effect of \u03b2-adrenoceptor blockade in patients with breast cancer undergoing chemotherapy. <i>Circ. Heart Fail.<\/i>, <b>6<\/b>, 420\u2013426 (2013).","DOI":"10.1161\/CIRCHEARTFAILURE.112.000055"},{"key":"79","doi-asserted-by":"crossref","unstructured":"79) Pituskin E, Mackey JR, Koshman S, Jassal D, Pitz M, Haykowsky MJ, Pagano JJ, Chow K, Thompson RB, Vos LJ, Ghosh S, Oudit GY, Ezekowitz JA, Paterson DI. Multidisciplinary approach to novel therapies in cardio-oncology research (MANTICORE 101-breast): a randomized trial for the prevention of trastuzumab-associated cardiotoxicity. <i>J. Clin. Oncol.<\/i>, <b>35<\/b>, 870\u2013877 (2017).","DOI":"10.1200\/JCO.2016.68.7830"},{"key":"80","doi-asserted-by":"crossref","unstructured":"80) Wang J, Hanada K, Staus DP, Makara MA, Dahal GR, Chen Q, Ahles A, Engelhardt S, Rockman HA. G\u03b1i is required for carvedilol-induced \u03b21 adrenergic receptor \u03b2-arrestin biased signaling. <i>Nat. Commun.<\/i>, <b>8<\/b>, 1706 (2017).","DOI":"10.1038\/s41467-017-01855-z"},{"key":"81","unstructured":"81) Armenian SH, Lacchetti C, Barac A, <i>et al.<\/i> Prevention and monitoring of cardiac dysfunction in survivors of adult cancers: American Society of Clinical Oncology Clinical Practice Guideline. <i>J. Clin. Oncol.<\/i>, <b>35<\/b>, 893\u2013911 (2017)."},{"key":"82","doi-asserted-by":"crossref","unstructured":"82) Akpek M, Ozdogru I, Sahin O, Inanc M, Dogan A, Yazici C, Berk V, Karaca H, Kalay N, Oguzhan A, Ergin A. Protective effects of spironolactone against anthracycline-induced cardiomyopathy. <i>Eur. J. Heart Fail.<\/i>, <b>17<\/b>, 81\u201389 (2015).","DOI":"10.1002\/ejhf.196"},{"key":"83","doi-asserted-by":"crossref","unstructured":"83) Boekhout AH, Gietema JA, Milojkovic Kerklaan B, <i>et al.<\/i> Angiotensin II\u2013receptor inhibition with candesartan to prevent trastuzumab-related cardiotoxic effects in patients with early breast cancer. <i>JAMA Oncol.<\/i>, <b>2<\/b>, 1030 (2016).","DOI":"10.1001\/jamaoncol.2016.1726"},{"key":"84","doi-asserted-by":"crossref","unstructured":"84) Gulati G, Heck SL, Ree AH, Hoffmann P, Schulz-Menger J, Fagerland MW, Gravdehaug B, von Knobelsdorff-Brenkenhoff F, Bratland \u00c5, Stor\u00e5s TH, Hagve T-A, R\u00f8sj\u00f8 H, Steine K, Geisler J, Omland T. Prevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA): a 2\u2009\u00d7\u20092 factorial, randomized, placebo-controlled, double-blind clinical trial of candesartan and metoprolol. <i>Eur. Heart J.<\/i>, <b>37<\/b>, 1671\u20131680 (2016).","DOI":"10.1093\/eurheartj\/ehw022"},{"key":"85","doi-asserted-by":"crossref","unstructured":"85) McMurray JJV, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, Rouleau JL, Shi VC, Solomon SD, Swedberg K, Zile MR. Angiotensin\u2013neprilysin inhibition versus enalapril in heart failure. <i>N. Engl. J. Med.<\/i>, <b>371<\/b>, 993\u20131004 (2014).","DOI":"10.1056\/NEJMoa1409077"},{"key":"86","doi-asserted-by":"crossref","unstructured":"86) Gregorietti V, Fernandez TL, Costa D, Chahla EO, Daniele AJ. Use of Sacubitril\/valsartan in patients with cardio toxicity and heart failure due to chemotherapy. <i>Cardiooncology<\/i>, <b>6<\/b>, 24 (2020).","DOI":"10.1186\/s40959-020-00078-4"},{"key":"87","doi-asserted-by":"crossref","unstructured":"87) Sobiborowicz-Sadowska AM, Kami\u0144ska K, Cudnoch-J\u0119drzejewska A. Neprilysin inhibition in the prevention of anthracycline-induced cardiotoxicity. <i>Cancers<\/i> (Basel), <b>15<\/b>, 312 (2023).","DOI":"10.3390\/cancers15010312"},{"key":"88","doi-asserted-by":"crossref","unstructured":"88) Hsia DS, Grove O, Cefalu WT. An update on sodium-glucose co-transporter-2 inhibitors for the treatment of diabetes mellitus. <i>Curr. Opin. Endocrinol. Diabetes Obes.<\/i>, <b>24<\/b>, 73\u201379 (2017).","DOI":"10.1097\/MED.0000000000000311"},{"key":"89","doi-asserted-by":"crossref","unstructured":"89) Chen S, Coronel R, Hollmann MW, Weber NC, Zuurbier CJ. Direct cardiac effects of SGLT2 inhibitors. <i>Cardiovasc. Diabetol.<\/i>, <b>21<\/b>, 45 (2022).","DOI":"10.1186\/s12933-022-01480-1"},{"key":"90","doi-asserted-by":"crossref","unstructured":"90) Elrakaybi A, Laubner K, Zhou Q, Hug MJ, Seufert J. Cardiovascular protection by SGLT2 inhibitors\u2014do anti-inflammatory mechanisms play a role? <i>Mol. Metab.<\/i>, <b>64<\/b>, 101549 (2022).","DOI":"10.1016\/j.molmet.2022.101549"},{"key":"91","doi-asserted-by":"crossref","unstructured":"91) Angsutararux P, Luanpitpong S, Issaragrisil S. Chemotherapy-induced cardiotoxicity: overview of the roles of oxidative stress. <i>Oxid. Med. Cell. Longev.<\/i>, <b>2015<\/b>, 795602\u201313 (2015).","DOI":"10.1155\/2015\/795602"},{"key":"92","doi-asserted-by":"crossref","unstructured":"92) Min J, Wu L, Liu Y, Song G, Deng Q, Jin W, Yu W, Abudureyimu M, Pei Z, Ren J. Empagliflozin attenuates trastuzumab-induced cardiotoxicity through suppression of DNA damage and ferroptosis. <i>Life Sci.<\/i>, <b>312<\/b>, 121207 (2023).","DOI":"10.1016\/j.lfs.2022.121207"},{"key":"93","doi-asserted-by":"crossref","unstructured":"93) Bagchi AK, Malik A, Akolkar G, Zimmer A, Bell\u00f3-Klein A, De Angelis K, Jassal DS, Fini MA, Stenmark KR, Singal PK. Study of ER stress and apoptotic proteins in the heart and tumor exposed to doxorubicin. <i>Biochim. Biophys. Acta Mol. Cell Res.<\/i>, <b>1868<\/b>, 119039 (2021).","DOI":"10.1016\/j.bbamcr.2021.119039"},{"key":"94","doi-asserted-by":"crossref","unstructured":"94) Chang WT, Lin YW, Ho CH, Chen ZC, Liu PY, Shih JY. Dapagliflozin suppresses ER stress and protects doxorubicin-induced cardiotoxicity in breast cancer patients. <i>Arch. Toxicol.<\/i>, <b>95<\/b>, 659\u2013671 (2021).","DOI":"10.1007\/s00204-020-02951-8"},{"key":"95","doi-asserted-by":"crossref","unstructured":"95) Fang X, Ardehali H, Min J, Wang F. The molecular and metabolic landscape of iron and ferroptosis in cardiovascular disease. <i>Nat. Rev. Cardiol.<\/i>, <b>20<\/b>, 7\u201323 (2023).","DOI":"10.1038\/s41569-022-00735-4"},{"key":"96","doi-asserted-by":"crossref","unstructured":"96) Beretta GL. Ferroptosis-induced cardiotoxicity and antitumor drugs. <i>Curr. Med. Chem.<\/i>, <b>31<\/b>, 4935\u20134957 (2024).","DOI":"10.2174\/0929867331666230719124453"},{"key":"97","doi-asserted-by":"crossref","unstructured":"97) Herring RA, Shojaee-Moradie F, Stevenage M, Parsons I, Jackson N, Mendis J, Middleton B, Umpleby AM, Fielding BA, Davies M, Russell-Jones DL. The SGLT2 inhibitor dapagliflozin increases the oxidation of ingested fatty acids to ketones in type 2 diabetes. <i>Diabetes Care<\/i>, <b>45<\/b>, 1408\u20131415 (2022).","DOI":"10.2337\/dc21-2043"},{"key":"98","doi-asserted-by":"crossref","unstructured":"98) Oh CM, Cho S, Jang JY, Kim H, Chun S, Choi M, Park S, Ko Y. Cardioprotective potential of an SGLT2 inhibitor against doxorubicin-induced heart failure. <i>Korean Circ. J.<\/i>, <b>49<\/b>, 1183\u20131195 (2019).","DOI":"10.4070\/kcj.2019.0180"},{"key":"99","doi-asserted-by":"crossref","unstructured":"99) Repp ML, Edwards MD, Burch CS, Rao A, Chinyere IR. PCSK9 inhibitors and anthracyclines: the future of cardioprotection in cardio-oncology. <i>Hearts<\/i> (Basel), <b>5<\/b>, 375\u2013388 (2024).","DOI":"10.3390\/hearts5030027"},{"key":"100","doi-asserted-by":"crossref","unstructured":"100) Safaeian L, Mirian M, Bahrizadeh S. Evolocumab, a PCSK9 inhibitor, protects human endothelial cells against H<sub>2<\/sub>O<sub>2<\/sub>-induced oxidative stress. <i>Arch. Physiol. Biochem.<\/i>, <b>128<\/b>, 1681\u20131686 (2022).","DOI":"10.1080\/13813455.2020.1788605"},{"key":"101","doi-asserted-by":"crossref","unstructured":"101) Momtazi-Borojeni AA, Sabouri-Rad S, Gotto AM Jr, Pirro M, Banach M, Awan Z, Barreto GE, Sahebkar A. PCSK9 and inflammation: a review of experimental and clinical evidence. <i>Eur. Heart J. Cardiovasc. Pharmacother.<\/i>, <b>5<\/b>, 237\u2013245 (2019).","DOI":"10.1093\/ehjcvp\/pvz022"},{"key":"102","doi-asserted-by":"crossref","unstructured":"102) Zeng J, Tao J, Xi L, Wang Z, Liu L. PCSK9 mediates the oxidative low-density lipoprotein-induced pyroptosis of vascular endothelial cells <i>via<\/i> the UQCRC1\/ROS pathway. <i>Int. J. Mol. Med.<\/i>, <b>47<\/b>, 53 (2021).","DOI":"10.3892\/ijmm.2021.4886"}],"container-title":["Biological and Pharmaceutical Bulletin"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/48\/9\/48_b25-00235\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T03:52:33Z","timestamp":1757130753000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/48\/9\/48_b25-00235\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,1]]},"references-count":102,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1248\/bpb.b25-00235","relation":{},"ISSN":["0918-6158","1347-5215"],"issn-type":[{"value":"0918-6158","type":"print"},{"value":"1347-5215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,1]]},"article-number":"b25-00235"}}